Inspire Medical Systems Inc. Reports Strong Growth in 2025 Annual Results
Inspire Medical Systems Inc., a leader in medical technology focused on innovative solutions for obstructive sleep apnea (OSA), has unveiled its 2025 annual report, showcasing remarkable growth in revenue and net income. The company’s commitment to advancing the Inspire system, the first FDA-approved neurostimulation device for moderate to severe OSA, has solidified its position in the market, despite facing rising competition and operational challenges.
1. Overview of Performance
For the fiscal year ending December 31, 2025, Inspire Medical Systems reported total revenue of $912.0 million, a significant increase of 13.6% compared to $802.8 million in 2024. This growth was fueled primarily by a remarkable $101 million surge in U.S. sales, alongside an $8.1 million increase in international revenue.
The Inspire system continues to be marketed through a direct sales organization to hospitals and surgery centers across the United States, while also being distributed in select European and Asian markets. The company’s strategy hinges on engaging healthcare providers and leveraging direct-to-consumer marketing to raise awareness about the benefits of Inspire therapy.
Financial Highlights
- Revenue: $912.0 million in 2025, up from $802.8 million in 2024.
- Gross Margin: Improved to 85.4% from 84.7% in the previous year.
- Net Income: Jumped to $145.4 million from $53.5 million in 2024, marking a significant recovery from the net loss of $21.2 million recorded in 2023.
- Accumulated Deficit: As of December 31, 2025, the accumulated deficit stood at $146.5 million.
Research and Development Investments
In 2025, Inspire Medical Systems continued to allocate significant resources to research and development (R&D), investing $103.2 million, down from $114.1 million in 2024. This reduction was primarily due to fewer ongoing development costs, although employee-related expenses rose. The focal point of R&D efforts remains the enhancement of the Inspire therapy, particularly following the FDA approval of the Inspire V neurostimulator in August 2024, which was launched in the U.S. market in May 2025.
2. Geographic Revenue Breakdown
In 2025, a staggering 95.6% of the company’s revenue was generated in the United States, with the remaining 4.4% coming from international markets. Inspire Medical Systems has established favorable coverage policies with a wide array of U.S. commercial payors, covering over 300 million lives, and has successfully secured Medicare coverage under specific criteria.
| Feb 2025 | Feb 2026 | |
|---|---|---|
Net Income | 53.50M | 145.4M |
Profit | 53.50M | 145.4M |
Net Income Continuing | 53.50M | 145.4M |
Income Tax Expense | 4.94M | -79.72M |
Pretax Income | 58.45M | 65.69M |
Non-operating Income | 22.37M | 14.74M |
Operating Income | 36.08M | 50.95M |
Revenue | 802.8M | 911.9M |
Costs and Expenses | 766.7M | 861.0M |
Cost of Revenue | 122.9M | 133.2M |
Operating Expenses | 643.7M | 727.8M |
Research & Development | 114.1M | 103.1M |
Selling, General & Administrative | 529.6M | 624.6M |
3. Financial Position and Liquidity
As of December 31, 2025, Inspire Medical Systems reported total assets of $907.3 million, which includes cash, cash equivalents, and available-for-sale debt securities totaling $404.6 million, although this is down from $516.5 million in 2024. The company’s working capital stood at $487.6 million, reflecting a decrease from the previous year.
Cash Flow Insights
The cash flow statement indicates a net change in cash of -$45.33 million for 2025. Key drivers of this decline included substantial share repurchases and inventory investments. Nonetheless, the company projects that its existing cash reserves, combined with operational cash flows, will sufficiently meet liquidity needs for at least the next 12 months.
| Feb 2025 | Feb 2026 | |
|---|---|---|
Net Change in Cash | -35.38M | -45.33M |
Effect of Exchange Rate Changes | -118K | -310K |
Net Cash from Operating Activities | 130.2M | 116.9M |
Operating Profit | 53.50M | 145.4M |
Adjustment to Operating Profit | 76.73M | -28.44M |
Net Cash from Investing Activities | -113.1M | 21.44M |
Investments | 73.99M | -59.94M |
Productive Assets | 39.12M | 38.49M |
Net Cash from Financing Activities | -52.39M | -183.4M |
Equity Issuance/Repurchase | -47.22M | -160.4M |
Other Financing Activities | -5.16M | -23.04M |
4. Market Challenges and Competitive Landscape
Despite its successes, Inspire Medical Systems faces growing competition from emerging treatments, particularly glucagon-like peptide 1 (GLP-1) medications that have gained traction as weight-loss drugs. The approval of tirzepatide for treating OSA in patients with obesity in late 2024 poses potential challenges to the demand for Inspire systems. However, the company remains optimistic that many patients will continue to require Inspire therapy due to the specific airway issues addressed by its technology.
5. Conclusion
Overall, Inspire Medical Systems Inc. has demonstrated impressive growth in both revenue and profitability in 2025, positioning itself as a leader in the medical technology space for OSA treatment. With a strong focus on R&D and market expansion, the company is well-equipped to navigate the competitive landscape and continue addressing the needs of patients suffering from obstructive sleep apnea.
As Inspire looks to the future, maintaining operational efficiency while navigating challenges related to market adoption and competition will be pivotal in sustaining its momentum.
